Search

everythinglearnresearchcommunity

for

Search:↓

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A 38-year-old man from Poland, balding for 15 years, shared his hair regrowth progress after 4 months of using finasteride (fin), minoxidil (min), micro-needling, and infrared light treatments. He recently switched from finasteride to dutasteride.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

The user had high DHT levels after 8 months on dutasteride, questioning the drug's authenticity. They got dutasteride from a legitimate source and will update on progress.

The conversation is about a user switching from finasteride to dutasteride after 4 years due to continued hair recession and miniaturization. The user plans to gradually increase to 1mg of dutasteride daily.

The conversation is about a person sharing before and after pictures of their hair loss treatment, which includes Minoxidil, Finasteride, and Dutasteride. They discuss their own hair loss, particularly the recession of their temporal points.

A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

The conversation is a satirical discussion about a user joking that their dog is balding and needs hair loss treatments like finasteride, with others commenting on the creepiness of an AI-generated image of a dog with human features.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The conversation discusses a 13-month hair loss treatment update using dutasteride, minoxidil, nizoral, and a 1.5mm derma roller, with the original poster reporting no side effects and some improvement in hair thickness. Participants request before-and-after pictures with consistent hairstyles to better assess the treatment's effectiveness.

The conversation is about the preference for using a derma stamp over a derma roller for hair loss treatment, with users discussing its efficiency, needle material, replacement frequency, and personal experiences. Specific treatments mentioned include microneedling with a derma stamp.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The user experienced significant hair regrowth using a treatment regimen including finasteride, oral and topical minoxidil, RU58841, red light therapy, microneedling, and various supplements. They switched from dutasteride to finasteride due to side effects and reported improved results and well-being.

The user successfully improved their hair from Norwood 3 to 0.5 using finasteride, topical minoxidil, microneedling, and a hair peptide, and plans to maintain it with dutasteride. They are leaving the forum due to emotional distress caused by the community.

The conversation discusses hair loss treatments, including scalp massage, and the importance of blocking DHT for hair loss management. The user shares blood test results, which appear normal, and seeks advice on effective tests and treatments, expressing a preference for natural methods over medication.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.